Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma

Immunotherapy drugs are gaining popularity in the treatment of certain malignancies due to the success of these agents in recent clinical trials. Pembrolizumab is an immune checkpoint inhibitor that acts via binding to programmed cell death 1 (PD-1) receptors on T-cells, allowing for the constitutiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kichloo, Asim, Albosta, Michael S., McMahon, Shane, Movsesian, Kimberly, Wani, Farah, Jamal, Shakeel M., Aljadah, Michael, Singh, Jagmeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448133/
https://www.ncbi.nlm.nih.gov/pubmed/32830561
http://dx.doi.org/10.1177/2324709620951339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448133/
https://www.ncbi.nlm.nih.gov/pubmed/32830561
http://dx.doi.org/10.1177/2324709620951339

Ejemplares similares